Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Cell

Retrieve available abstracts of 177 articles:
HTML format



Single Articles


    November 2022
  1. YAN L, Huang Y, Ge J, Liu Z, et al
    A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analog inhibitors.
    Cell. 2022;185:4347-4360.
    PubMed     Abstract available


  2. BUCKNER CM, Kardava L, El Merhebi O, Narpala SR, et al
    Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses.
    Cell. 2022;185:4333-4346.
    PubMed     Abstract available


  3. LE NOUEN C, Nelson CE, Liu X, Park HS, et al
    Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.
    Cell. 2022 Nov 10:S0092-8674(22)01418-0. doi: 10.1016/j.cell.2022.
    PubMed     Abstract available


    October 2022
  4. PHILIPS RL, Wang Y, Cheon H, Kanno Y, et al
    The JAK-STAT pathway at 30: Much learned, much more to do.
    Cell. 2022;185:3857-3876.
    PubMed     Abstract available


  5. KIMURA I, Yamasoba D, Tamura T, Nao N, et al
    Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
    Cell. 2022;185:3992-4007.
    PubMed     Abstract available


  6. TAFT JM, Weber CR, Gao B, Ehling RA, et al
    Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain.
    Cell. 2022;185:4008-4022.
    PubMed     Abstract available


    September 2022
  7. ACHARYA D, Reis R, Volcic M, Liu G, et al
    Actin cytoskeleton remodeling primes RIG-I-like receptor activation.
    Cell. 2022;185:3588-3602.
    PubMed     Abstract available


  8. FRANK F, Keen MM, Rao A, Bassit L, et al
    Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests.
    Cell. 2022;185:3603-3616.
    PubMed     Abstract available


  9. ROTHENBURG S, Yang Z, Beard P, Sawyer SL, et al
    Monkeypox emergency: Urgent questions and perspectives.
    Cell. 2022;185:3279-3281.
    PubMed     Abstract available


    August 2022
  10. CASANOVA JL, Abel L
    From rare disorders of immunity to common determinants of infection: Following the mechanistic thread.
    Cell. 2022;185:3086-3103.
    PubMed     Abstract available


  11. DOLTON G, Rius C, Hasan MS, Wall A, et al
    Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.
    Cell. 2022;185:2936-2951.
    PubMed     Abstract available


  12. LI L, Liao H, Meng Y, Li W, et al
    Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1.
    Cell. 2022;185:2952-2960.
    PubMed     Abstract available


    July 2022
  13. TUEKPRAKHON A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, et al
    Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
    Cell. 2022;185:2422-2433.
    PubMed     Abstract available


  14. KAO J, Frankland PW
    COVID fog demystified.
    Cell. 2022;185:2391-2393.
    PubMed     Abstract available


  15. FERNANDEZ-CASTANEDA A, Lu P, Geraghty AC, Song E, et al
    Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation.
    Cell. 2022;185:2452-2468.
    PubMed     Abstract available


  16. ZHANG Z, Mateus J, Coelho CH, Dan JM, et al
    Humoral and cellular immune memory to four COVID-19 vaccines.
    Cell. 2022;185:2434-2451.
    PubMed     Abstract available


    June 2022
  17. XU K, Gao P, Liu S, Lu S, et al
    Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
    Cell. 2022;185:2265-2278.
    PubMed     Abstract available


  18. NUTALAI R, Zhou D, Tuekprakhon A, Ginn HM, et al
    Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
    Cell. 2022;185:2116-2131.
    PubMed     Abstract available


  19. YAMASOBA D, Kimura I, Nasser H, Morioka Y, et al
    Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
    Cell. 2022;185:2103-2115.
    PubMed     Abstract available


  20. CHATURVEDI S, Pablo M, Wolf M, Rosas-Rivera D, et al
    Disrupting autorepression circuitry generates "open-loop lethality" to yield escape-resistant antiviral agents.
    Cell. 2022;185:2086-2102.
    PubMed     Abstract available


    May 2022
  21. YEUNG ML, Teng JLL, Yuen KY
    Response to Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity.
    Cell. 2022;185:1840-1841.
    PubMed    


  22. BATLLE D, Monteil V, Garreta E, Hassler L, et al
    Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity.
    Cell. 2022;185:1837-1839.
    PubMed    


  23. GOEL RR, Painter MM, Lundgreen KA, Apostolidis SA, et al
    Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine.
    Cell. 2022;185:1875-1887.
    PubMed     Abstract available


    April 2022
  24. YING B, Scheaffer SM, Whitener B, Liang CY, et al
    Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
    Cell. 2022;185:1572-1587.
    PubMed     Abstract available


  25. GAGNE M, Moliva JI, Foulds KE, Andrew SF, et al
    mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.
    Cell. 2022;185:1556-1571.
    PubMed     Abstract available


  26. SERVELLITA V, Syed AM, Morris MK, Brazer N, et al
    Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
    Cell. 2022;185:1539-1548.
    PubMed     Abstract available


  27. CHANDRASHEKAR A, Yu J, McMahan K, Jacob-Dolan C, et al
    Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
    Cell. 2022;185:1549-1555.
    PubMed     Abstract available


  28. RODDA LB, Morawski PA, Pruner KB, Fahning ML, et al
    Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.
    Cell. 2022;185:1588-1601.
    PubMed     Abstract available



  29. Bringing research to the intensive care setting.
    Cell. 2022;185:1275-1278.
    PubMed     Abstract available



  30. Learning lessons from lipids to make COVID-19 vaccines.
    Cell. 2022;185:1279-1282.
    PubMed     Abstract available


  31. LI C, Zhan W, Yang Z, Tu C, et al
    Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.
    Cell. 2022;185:1389-1401.
    PubMed     Abstract available


  32. YEN M, Ren J, Liu Q, Glassman CR, et al
    Facile discovery of surrogate cytokine agonists.
    Cell. 2022;185:1414-1430.
    PubMed     Abstract available


  33. QU L, Yi Z, Shen Y, Lin L, et al
    Circular RNA vaccines against SARS-CoV-2 and emerging variants.
    Cell. 2022 Apr 1. pii: S0092-8674(22)00394-4. doi: 10.1016/j.cell.2022.
    PubMed     Abstract available


    March 2022
  34. TANGYE SG, Burnett DL, Bull RA
    Getting to the (germinal) center of humoral immune responses to SARS-CoV-2.
    Cell. 2022;185:945-948.
    PubMed     Abstract available


  35. ZAZHYTSKA M, Kodra A, Hoagland DA, Frere J, et al
    Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia.
    Cell. 2022;185:1052-1064.
    PubMed     Abstract available


  36. ROLTGEN K, Nielsen SCA, Silva O, Younes SF, et al
    Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.
    Cell. 2022;185:1025-1040.
    PubMed     Abstract available



  37. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
    Cell. 2022;185:916-938.
    PubMed     Abstract available


  38. SU Y, Yuan D, Chen DG, Ng RH, et al
    Multiple early factors anticipate post-acute COVID-19 sequelae.
    Cell. 2022;185:881-895.
    PubMed     Abstract available


  39. AFKHAMI S, D'Agostino MR, Zhang A, Stacey HD, et al
    Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Cell. 2022;185:896-915.
    PubMed     Abstract available


  40. TARKE A, Coelho CH, Zhang Z, Dan JM, et al
    SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
    Cell. 2022;185:847-859.
    PubMed     Abstract available


  41. CUI Z, Liu P, Wang N, Wang L, et al
    Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron.
    Cell. 2022;185:860-871.
    PubMed     Abstract available


    February 2022
  42. BORRIELLO F, Poli V, Shrock E, Spreafico R, et al
    An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.
    Cell. 2022;185:614-629.
    PubMed     Abstract available


  43. MUDD PA, Minervina AA, Pogorelyy MV, Turner JS, et al
    SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
    Cell. 2022;185:603-613.
    PubMed     Abstract available


  44. WESEMANN DR
    Omicron's message on vaccines: Boosting begets breadth.
    Cell. 2022;185:411-413.
    PubMed     Abstract available


  45. SIDDLE KJ, Krasilnikova LA, Moreno GK, Schaffner SF, et al
    Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak.
    Cell. 2022;185:485-492.
    PubMed     Abstract available


  46. GEORG P, Astaburuaga-Garcia R, Bonaguro L, Brumhard S, et al
    Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
    Cell. 2022;185:493-512.
    PubMed     Abstract available


  47. HOFFMANN M, Kruger N, Schulz S, Cossmann A, et al
    The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Cell. 2022;185:447-456.
    PubMed     Abstract available


  48. COLLINS F
    Francis Collins: Reflections on being the NIH Director.
    Cell. 2022;185:401-406.
    PubMed     Abstract available


    December 2021
  49. GRUBAUGH ND, Cobey S
    Of variants and vaccines.
    Cell. 2021;184:6222-6223.
    PubMed     Abstract available


  50. TERMINI CM, Rutaganira FUN, Palavicino-Maggio CB, Spriggs CC, et al
    Using virtual interviewing to create a more accessible hybrid academic job market.
    Cell. 2021;184:6217-6221.
    PubMed     Abstract available


  51. WENDISCH D, Dietrich O, Mari T, von Stillfried S, et al
    SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
    Cell. 2021;184:6243-6261.
    PubMed     Abstract available


  52. BUSHMAN M, Kahn R, Taylor BP, Lipsitch M, et al
    Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape.
    Cell. 2021;184:6229-6242.
    PubMed     Abstract available


  53. BRIAND SC, Cinelli M, Nguyen T, Lewis R, et al
    Infodemics: A new challenge for public health.
    Cell. 2021;184:6010-6014.
    PubMed     Abstract available


  54. XIAO Y, Lidsky PV, Shirogane Y, Aviner R, et al
    A defective viral genome strategy elicits broad protective immunity against respiratory viruses.
    Cell. 2021;184:6037-6051.
    PubMed     Abstract available


  55. CHATURVEDI S, Vasen G, Pablo M, Chen X, et al
    Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
    Cell. 2021;184:6022-6036.
    PubMed     Abstract available


    November 2021
  56. KHAN M, Yoo SJ, Clijsters M, Backaert W, et al
    Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb.
    Cell. 2021;184:5932-5949.
    PubMed     Abstract available


  57. KUMAR S, Javed R, Mudd M, Pallikkuth S, et al
    Mammalian hybrid pre-autophagosomal structure HyPAS generates autophagosomes.
    Cell. 2021;184:5950-5969.
    PubMed     Abstract available


  58. PAYNE RP, Longet S, Austin JA, Skelly DT, et al
    Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
    Cell. 2021;184:5699-5714.
    PubMed     Abstract available


    October 2021
  59. CROSS G, Ho JSY, Zacharias W, Jeyasekharan AD, et al
    Emergency drug use in a pandemic: Harsh lessons from COVID-19.
    Cell. 2021;184:5497-5500.
    PubMed     Abstract available



  60. Persistent progress.
    Cell. 2021;184:5293-5296.
    PubMed     Abstract available


  61. SHAPIRO L, Losick R
    Delivering the message: How a novel technology enabled the rapid development of effective vaccines.
    Cell. 2021;184:5271-5274.
    PubMed     Abstract available


    September 2021
  62. MARTIN DP, Weaver S, Tegally H, San JE, et al
    The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages.
    Cell. 2021;184:5189-5200.
    PubMed     Abstract available


  63. CEVIK M, Grubaugh ND, Iwasaki A, Openshaw P, et al
    COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
    Cell. 2021;184:5077-5081.
    PubMed     Abstract available


  64. JACKSON B, Boni MF, Bull MJ, Colleran A, et al
    Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic.
    Cell. 2021;184:5179-5188.
    PubMed     Abstract available



  65. Building and supporting identity in peer review.
    Cell. 2021;184:5071-5072.
    PubMed    


  66. ZELLER M, Gangavarapu K, Anderson C, Smither AR, et al
    Emergence of an early SARS-CoV-2 epidemic in the United States.
    Cell. 2021;184:4939-4952.
    PubMed     Abstract available


  67. SPOSITO B, Broggi A, Pandolfi L, Crotta S, et al
    The interferon landscape along the respiratory tract impacts the severity of COVID-19.
    Cell. 2021;184:4953-4968.
    PubMed     Abstract available


  68. HOLMES EC, Goldstein SA, Rasmussen AL, Robertson DL, et al
    The origins of SARS-CoV-2: A critical review.
    Cell. 2021;184:4848-4856.
    PubMed     Abstract available


  69. ZIEGLER CGK, Miao VN, Owings AH, Navia AW, et al
    Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19.
    Cell. 2021;184:4713-4733.
    PubMed     Abstract available


    August 2021
  70. KARLSSON EA, Duong V
    The continuing search for the origins of SARS-CoV-2.
    Cell. 2021;184:4373-4374.
    PubMed     Abstract available


  71. KANG L, He G, Sharp AK, Wang X, et al
    A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation.
    Cell. 2021;184:4392-4400.
    PubMed     Abstract available


  72. NATHAN A, Rossin EJ, Kaseke C, Park RJ, et al
    Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
    Cell. 2021;184:4401-4413.
    PubMed     Abstract available


  73. ZHOU H, Ji J, Chen X, Bi Y, et al
    Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses.
    Cell. 2021;184:4380-4391.
    PubMed     Abstract available


  74. LIU C, Ginn HM, Dejnirattisai W, Supasa P, et al
    Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
    Cell. 2021;184:4220-4236.
    PubMed     Abstract available


  75. LI D, Edwards RJ, Manne K, Martinez DR, et al
    In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
    Cell. 2021;184:4203-4219.
    PubMed     Abstract available


    July 2021
  76. RESCIGNO M
    Unraveling the long-term effect of influenza vaccines.
    Cell. 2021;184:3845-3847.
    PubMed     Abstract available


  77. WEINGARTEN-GABBAY S, Klaeger S, Sarkizova S, Pearlman LR, et al
    Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
    Cell. 2021;184:3962-3980.
    PubMed     Abstract available


  78. COPIN R, Baum A, Wloga E, Pascal KE, et al
    The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
    Cell. 2021;184:3949-3961.
    PubMed     Abstract available


    June 2021
  79. YAN L, Yang Y, Li M, Zhang Y, et al
    Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading.
    Cell. 2021;184:3474-3485.
    PubMed     Abstract available


  80. LIU K, Pan X, Li L, Yu F, et al
    Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species.
    Cell. 2021;184:3438-3451.
    PubMed     Abstract available


  81. LIU Y, Soh WT, Kishikawa JI, Hirose M, et al
    An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
    Cell. 2021;184:3452-3466.
    PubMed     Abstract available


  82. HE X, Chandrashekar A, Zahn R, Wegmann F, et al
    Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
    Cell. 2021;184:3467-3473.
    PubMed     Abstract available


  83. HAO Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, et al
    Integrated analysis of multimodal single-cell data.
    Cell. 2021;184:3573-3587.
    PubMed     Abstract available


  84. DENG X, Garcia-Knight MA, Khalid MM, Servellita V, et al
    Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
    Cell. 2021;184:3426-3437.
    PubMed     Abstract available


  85. WIMMERS F, Donato M, Kuo A, Ashuach T, et al
    The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.
    Cell. 2021 Jun 22. pii: S0092-8674(21)00692-9. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  86. CORTI D, Purcell LA, Snell G, Veesler D, et al
    Tackling COVID-19 with neutralizing monoclonal antibodies.
    Cell. 2021;184:3086-3108.
    PubMed     Abstract available


  87. SCHEID JF, Barnes CO, Eraslan B, Hudak A, et al
    B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.
    Cell. 2021;184:3205-3221.
    PubMed     Abstract available


  88. ASARNOW D, Wang B, Lee WH, Hu Y, et al
    Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
    Cell. 2021;184:3192-3204.
    PubMed     Abstract available


    May 2021
  89. BAUMER Y, Powell-Wiley TM
    Interdisciplinary approaches are fundamental to decode the biology of adversity.
    Cell. 2021;184:2797-2801.
    PubMed     Abstract available


  90. GARRETT ME, Galloway J, Chu HY, Itell HL, et al
    High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
    Cell. 2021;184:2927-2938.
    PubMed     Abstract available


  91. DEJNIRATTISAI W, Zhou D, Supasa P, Liu C, et al
    Antibody evasion by the P.1 strain of SARS-CoV-2.
    Cell. 2021;184:2939-2954.
    PubMed     Abstract available


  92. WILLIAMS WB, Meyerhoff RR, Edwards RJ, Li H, et al
    Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
    Cell. 2021 May 18. pii: S0092-8674(21)00577-8. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  93. ALPERT T, Brito AF, Lasek-Nesselquist E, Rothman J, et al
    Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States.
    Cell. 2021;184:2595-2604.
    PubMed     Abstract available


  94. WASHINGTON NL, Gangavarapu K, Zeller M, Bolze A, et al
    Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
    Cell. 2021;184:2587-2594.
    PubMed     Abstract available


  95. HO JSY, Mok BW, Campisi L, Jordan T, et al
    TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
    Cell. 2021;184:2618-2632.
    PubMed     Abstract available


  96. CLARK SA, Clark LE, Pan J, Coscia A, et al
    SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
    Cell. 2021;184:2605-2617.
    PubMed     Abstract available


  97. QIU X, Hanage WP, Taylor BP
    Coming to America: Genomic surveillance and how B.1.1.7 arrived in the US.
    Cell. 2021;184:2532-2534.
    PubMed     Abstract available


    April 2021
  98. LEBLANC EV, Colpitts CC
    SARS-CoV-2 RNA: Exclusive friends and common foes.
    Cell. 2021;184:2276-2278.
    PubMed     Abstract available


  99. BOEHM JS
    The power of parent scientists.
    Cell. 2021;184:2263-2270.
    PubMed     Abstract available


  100. HOFFMANN M, Arora P, Gross R, Seidel A, et al
    SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
    Cell. 2021;184:2384-2393.
    PubMed     Abstract available


  101. SURYADEVARA N, Shrihari S, Gilchuk P, VanBlargan LA, et al
    Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
    Cell. 2021;184:2316-2331.
    PubMed     Abstract available


  102. FABIUS JM, Krogan NJ
    Creating collaboration by breaking down scientific barriers.
    Cell. 2021;184:2271-2275.
    PubMed     Abstract available


  103. MCCALLUM M, De Marco A, Lempp FA, Tortorici MA, et al
    N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
    Cell. 2021;184:2332-2347.
    PubMed     Abstract available


  104. GARCIA-BELTRAN WF, Lam EC, St Denis K, Nitido AD, et al
    Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
    Cell. 2021;184:2372-2383.
    PubMed     Abstract available


  105. FLYNN RA, Belk JA, Qi Y, Yasumoto Y, et al
    Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions.
    Cell. 2021;184:2394-2411.
    PubMed     Abstract available


  106. ZHOU D, Dejnirattisai W, Supasa P, Liu C, et al
    Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
    Cell. 2021;184:2348-2361.
    PubMed     Abstract available



  107. The origins of viral infection sleuth.
    Cell. 2021;184:1960-1961.
    PubMed     Abstract available


  108. SCHNEIDER JL, Rowe JH, Garcia-de-Alba C, Kim CF, et al
    The aging lung: Physiology, disease, and immunity.
    Cell. 2021;184:1990-2019.
    PubMed     Abstract available


  109. MILLS RJ, Humphrey SJ, Fortuna PRJ, Lor M, et al
    BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
    Cell. 2021;184:2167-2182.
    PubMed     Abstract available


  110. DEJNIRATTISAI W, Zhou D, Ginn HM, Duyvesteyn HME, et al
    The antigenic anatomy of SARS-CoV-2 receptor binding domain.
    Cell. 2021;184:2183-2200.
    PubMed     Abstract available


  111. SUPASA P, Zhou D, Dejnirattisai W, Liu C, et al
    Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
    Cell. 2021;184:2201-2211.
    PubMed     Abstract available


  112. YEUNG ML, Teng JLL, Jia L, Zhang C, et al
    Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
    Cell. 2021;184:2212-2228.
    PubMed     Abstract available


  113. ZHANG X, Liu Y, Liu J, Bailey AL, et al
    A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
    Cell. 2021;184:2229-2238.
    PubMed     Abstract available


  114. PEIRIS JSM
    One world, one health.
    Cell. 2021;184:1956-1959.
    PubMed     Abstract available


  115. SCHULTZE JL, Aschenbrenner AC
    COVID-19 and the human innate immune system.
    Cell. 2021;184:1671-1692.
    PubMed     Abstract available


  116. YU B, Qi Y, Li R, Shi Q, et al
    B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells.
    Cell. 2021;184:1790-1803.
    PubMed     Abstract available


  117. LIU C, Martins AJ, Lau WW, Rachmaninoff N, et al
    Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19.
    Cell. 2021;184:1836-1857.
    PubMed     Abstract available


  118. WINKLER ES, Gilchuk P, Yu J, Bailey AL, et al
    Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
    Cell. 2021;184:1804-1820.
    PubMed     Abstract available


  119. ANDREANO E, Nicastri E, Paciello I, Pileri P, et al
    Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
    Cell. 2021;184:1821-1835.
    PubMed     Abstract available


  120. REN X, Wen W, Fan X, Hou W, et al
    COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas.
    Cell. 2021;184:1895-1913.
    PubMed     Abstract available


  121. SUN L, Li P, Ju X, Rao J, et al
    In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
    Cell. 2021;184:1865-1883.
    PubMed     Abstract available


  122. ANDERSON EM, Goodwin EC, Verma A, Arevalo CP, et al
    Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
    Cell. 2021;184:1858-1864.
    PubMed     Abstract available


    March 2021
  123. GEBRE MS, Brito LA, Tostanoski LH, Edwards DK, et al
    Novel approaches for vaccine development.
    Cell. 2021;184:1589-1603.
    PubMed     Abstract available


  124. SANDRONE S, Scott G, Anderson WJ, Musunuru K, et al
    Active learning-based STEM education for in-person and online learning.
    Cell. 2021;184:1409-1414.
    PubMed     Abstract available



  125. Scientific misinformation: A perfect storm, missteps, and moving forward.
    Cell. 2021;184:1402-1406.
    PubMed     Abstract available


  126. TOPOL EJ
    Messenger RNA vaccines against SARS-CoV-2.
    Cell. 2021;184:1401.
    PubMed     Abstract available


  127. PILLON NJ, Loos RJF, Marshall SM, Zierath JR, et al
    Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care.
    Cell. 2021;184:1530-1544.
    PubMed     Abstract available


  128. MANN ME, Hall LJ, Dulvy NK
    Scientific impact in a changing world.
    Cell. 2021;184:1407-1408.
    PubMed     Abstract available


  129. THOMSON EC, Rosen LE, Shepherd JG, Spreafico R, et al
    Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
    Cell. 2021;184:1171-1187.
    PubMed     Abstract available


  130. GRUBAUGH ND, Hodcroft EB, Fauver JR, Phelan AL, et al
    Public health actions to control new SARS-CoV-2 variants.
    Cell. 2021;184:1127-1132.
    PubMed     Abstract available


  131. BROUWER PJM, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, et al
    Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
    Cell. 2021;184:1188-1200.
    PubMed     Abstract available


  132. SOKAL A, Chappert P, Barba-Spaeth G, Roeser A, et al
    Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
    Cell. 2021;184:1201-1213.
    PubMed     Abstract available


    February 2021
  133. LI Q, Nie J, Wu J, Zhang L, et al
    SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
    Cell. 2021 Feb 23. pii: S0092-8674(21)00231-2. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  134. SETTE A, Crotty S
    Adaptive immunity to SARS-CoV-2 and COVID-19.
    Cell. 2021;184:861-880.
    PubMed     Abstract available


  135. NIE X, Qian L, Sun R, Huang B, et al
    Multi-organ proteomic landscape of COVID-19 autopsies.
    Cell. 2021;184:775-791.
    PubMed     Abstract available


  136. ATYEO C, Pullen KM, Bordt EA, Fischinger S, et al
    Compromised SARS-CoV-2-specific placental antibody transfer.
    Cell. 2021;184:628-642.
    PubMed     Abstract available


    January 2021
  137. GARCIA-BELTRAN WF, Lam EC, Astudillo MG, Yang D, et al
    COVID-19-neutralizing antibodies predict disease severity and survival.
    Cell. 2021;184:476-488.
    PubMed     Abstract available


  138. HOANG TN, Pino M, Boddapati AK, Viox EG, et al
    Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Cell. 2021;184:460-475.
    PubMed     Abstract available



  139. What happens next.
    Cell. 2021;184:291-292.
    PubMed    


  140. HOFFMANN HH, Schneider WM, Rozen-Gagnon K, Miles LA, et al
    TMEM41B Is a Pan-flavivirus Host Factor.
    Cell. 2021;184:133-148.
    PubMed     Abstract available


  141. WANG R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, et al
    Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.
    Cell. 2021;184:106-119.
    PubMed     Abstract available


  142. RODDA LB, Netland J, Shehata L, Pruner KB, et al
    Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
    Cell. 2021;184:169-183.
    PubMed     Abstract available


  143. KARKI R, Sharma BR, Tuladhar S, Williams EP, et al
    Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.
    Cell. 2021;184:149-168.
    PubMed     Abstract available


  144. VOLZ E, Hill V, McCrone JT, Price A, et al
    Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
    Cell. 2021;184:64-75.
    PubMed     Abstract available


  145. DANILOSKI Z, Jordan TX, Wessels HH, Hoagland DA, et al
    Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells.
    Cell. 2021;184:92-105.
    PubMed     Abstract available


  146. WEI J, Alfajaro MM, DeWeirdt PC, Hanna RE, et al
    Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.
    Cell. 2021;184:76-91.
    PubMed     Abstract available


    December 2020
  147. AVANZATO VA, Matson MJ, Seifert SN, Pryce R, et al
    Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
    Cell. 2020;183:1901-1912.
    PubMed     Abstract available


  148. ZOHAR T, Loos C, Fischinger S, Atyeo C, et al
    Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
    Cell. 2020;183:1508-1519.
    PubMed     Abstract available


  149. SU Y, Chen D, Yuan D, Lausted C, et al
    Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.
    Cell. 2020;183:1479-1495.
    PubMed     Abstract available


  150. CHEN Y, Zuiani A, Fischinger S, Mullur J, et al
    Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.
    Cell. 2020;183:1496-1507.
    PubMed     Abstract available


  151. GHOSH S, Dellibovi-Ragheb TA, Kerviel A, Pak E, et al
    beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway.
    Cell. 2020;183:1520-1535.
    PubMed     Abstract available


    November 2020
  152. WALLS AC, Fiala B, Schafer A, Wrenn S, et al
    Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Cell. 2020;183:1367-1382.
    PubMed     Abstract available


  153. MECKIFF BJ, Ramirez-Suastegui C, Fajardo V, Chee SJ, et al
    Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19.
    Cell. 2020;183:1340-1353.
    PubMed     Abstract available


  154. BANERJEE AK, Blanco MR, Bruce EA, Honson DD, et al
    SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses.
    Cell. 2020;183:1325-1339.
    PubMed     Abstract available


  155. AID M, Busman-Sahay K, Vidal SJ, Maliga Z, et al
    Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.
    Cell. 2020;183:1354-1366.
    PubMed     Abstract available


  156. KREYE J, Reincke SM, Kornau HC, Sanchez-Sendin E, et al
    A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Cell. 2020;183:1058-1069.
    PubMed     Abstract available


  157. LEIST SR, Dinnon KH 3rd, Schafer A, Tse LV, et al
    A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.
    Cell. 2020;183:1070-1085.
    PubMed     Abstract available


  158. RYDYZNSKI MODERBACHER C, Ramirez SI, Dan JM, Grifoni A, et al
    Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
    Cell. 2020;183:996-1012.
    PubMed     Abstract available


  159. PICCOLI L, Park YJ, Tortorici MA, Czudnochowski N, et al
    Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Cell. 2020;183:1024-1042.
    PubMed     Abstract available


  160. GRUBER CN, Patel RS, Trachtman R, Lepow L, et al
    Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).
    Cell. 2020;183:982-995.
    PubMed     Abstract available


  161. CLAUSEN TM, Sandoval DR, Spliid CB, Pihl J, et al
    SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
    Cell. 2020;183:1043-1057.
    PubMed     Abstract available


  162. CONSIGLIO CR, Cotugno N, Sardh F, Pou C, et al
    The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
    Cell. 2020;183:968-981.
    PubMed     Abstract available


    October 2020
  163. YURKOVETSKIY L, Wang X, Pascal KE, Tomkins-Tinch C, et al
    Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
    Cell. 2020;183:739-751.
    PubMed     Abstract available


  164. MUKHERJEE S
    Before Virus, After Virus: A Reckoning.
    Cell. 2020;183:308-314.
    PubMed     Abstract available


  165. IWASAKI A, Omer SB
    Why and How Vaccines Work.
    Cell. 2020;183:290-295.
    PubMed     Abstract available


  166. GOLDSTEIN JL
    The Spanish 1918 Flu and the COVID-19 Disease: The Art of Remembering and Foreshadowing Pandemics.
    Cell. 2020;183:285-289.
    PubMed     Abstract available


  167. LI W, Schafer A, Kulkarni SS, Liu X, et al
    High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.
    Cell. 2020;183:429-441.
    PubMed     Abstract available


  168. SEKINE T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, et al
    Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
    Cell. 2020;183:158-168.
    PubMed     Abstract available


  169. AU L, Boos LA, Swerdlow A, Byrne F, et al
    Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study.
    Cell. 2020;183:4-10.
    PubMed     Abstract available


  170. CANETE PF, Vinuesa CG
    COVID-19 Makes B Cells Forget, but T Cells Remember.
    Cell. 2020;183:13-15.
    PubMed     Abstract available


  171. HASSAN AO, Kafai NM, Dmitriev IP, Fox JM, et al
    A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
    Cell. 2020;183:169-184.
    PubMed     Abstract available


  172. IADECOLA C, Anrather J, Kamel H
    Effects of COVID-19 on the Nervous System.
    Cell. 2020;183:16-27.
    PubMed     Abstract available


  173. KANEKO N, Kuo HH, Boucau J, Farmer JR, et al
    Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.
    Cell. 2020;183:143-157.
    PubMed     Abstract available


    September 2020
  174. COLUBRI A, Kemball M, Sani K, Boehm C, et al
    Preventing Outbreaks through Interactive, Experiential Real-Life Simulations.
    Cell. 2020;182:1366-1371.
    PubMed     Abstract available


  175. SCHULTE-SCHREPPING J, Reusch N, Paclik D, Bassler K, et al
    Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.
    Cell. 2020;182:1419-1440.
    PubMed     Abstract available


  176. DU S, Cao Y, Zhu Q, Yu P, et al
    Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
    Cell. 2020 Sep 14. pii: S0092-8674(20)31232-0. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available


    August 2020
  177. GEITMANN A
    Travel Less. Make It Worthwhile.
    Cell. 2020;182:790-793.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: